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Abstract
Background: Early intensive blood pressure (BP) lowering remains the most promising treatment for acute
intracerebral hemorrhage (ICH), despite discordant results between clinical trials and potential variation in the
treatment effects by approach to control BP. As the third in a series of clinical trials on this topic, the INTEnsive care
bundle with blood pressure Reduction in Acute Cerebral hemorrhage Trial (INTERACT3) aims to determine the
effectiveness of a goal-directed care bundle protocol of early physiological control (intensive BP lowering, glycemic
control, and pyrexia treatment) and reversal of anticoagulation, in acute ICH.
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Methods: INTERACT3 is a pragmatic, international, multicenter, stepped-wedge (4 phases/3 steps), clusterrandomized controlled trial to determine the effectiveness of a multifaceted care package in adult (age ≥ 18 years)
patients (target 8360) with acute ICH (< 6 h of onset) recruited from 110 hospitals (average of 19 consecutive
patients per phase) in low- and middle-income countries. After a control phase, each hospital implements the
intervention (intensive BP lowering, target systolic < 140 mmHg; glucose control, target 6.1–7.8 mmol/L and 7.8–
10.0 mmol/L in those without and with diabetes mellitus, respectively; anti-pyrexia treatment to target body
temperature ≤ 37.5 °C; and reversal of anticoagulation, target international normalized ratio < 1.5 within 1 h).
Information will be obtained on demographic and baseline clinical characteristics, in-hospital management, and 7day outcomes. Central trained blinded assessors will conduct telephone interviews to assess physical function and
health-related quality of life at 6 months. The primary outcome is the modified Rankin scale (mRS) at 6 months
analyzed using ordinal logistic regression. The sample size of 8360 subjects provides 90% power (α = 0.05) to detect
a 5.6% absolute improvement (shift) in the primary outcome of the intervention versus control standard care, with
various assumptions.
Discussion: As the largest clinical trial in acute ICH, INTERACT3 is on schedule to provide an assessment of the
effectiveness of a widely applicable goal-directed care bundle for a serious condition in which a clearly proven
treatment has yet to be established.
Trial registration: ClinicalTrials.gov NCT03209258. Registered on 1 July 2017. Chinese Trial Registry ChiCTR-IOC17011787. Registered on 28 June 2017
Keywords: Stepped-wedge cluster-randomized trial, Clinical trial, Care bundle, management, Intracerebral
hemorrhage, Stroke
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Introduction
Background and rationale {6a}

Acute spontaneous intracerebral hemorrhage (ICH) is
the most severe type of stroke, for which two thirds of
patients either die or are disabled, and where the overall
rates and outcomes have remained relatively stable in
recent decades [1, 2]. Although ICH accounts for
approximately 10–20% of strokes in high-income countries, proportional frequencies and rates are much higher
in low- and middle-income countries (LMICs) causing
considerable personal, social, and economic burden in
large high-risk populations [3–5].
Although slow progress has been made in reliably
establishing effective medical (and surgical) treatments
for ICH, intensive blood pressure (BP) lowering is the
most attractive as it is relatively low-cost, widely applicable, and supported by strong epidemiological data for
the frequency and prognostic significance of hypertension in ICH [6]. This treatment appears safe and effective when given early after the onset of ICH [7] when
most of the bleeding occurs, defined as hematoma
growth or expansion [8]. Thus, BP lowering in the context of other active, supported, and organized care [9,
10] could provide large absolute benefits even if the benefits to individual patients are modest. Yet, there are ongoing concerns over the size of potential benefits and
harms [11] across different types of patients, which influence guideline recommendations and the unifying of
clinical practice [12]. There is also uncertainty over the
benefits of controlling other abnormal physiological variables, such as hyperglycemia [13, 14] and pyrexia [15], as
well in the reversal of anticoagulation [16], which are associated with hematoma growth and adverse outcomes
[17, 18], but where there are considerable challenges to
providing the necessary evidence from adequately powered randomized studies.
Clustering interventions together as part of a care
bundle have shown encouraging results. For example,
the Australian Quality in Acute Stroke Care (QASC)
cluster trial [19] showed that a protocol to manage
fever, hyperglycemia, and assessments of swallowing
function improved recovery for patients with acute
stroke, while a quality improvement “before-and-after”
evaluation of protocol involving anticoagulation
reversal, intensive BP lowering, and rapid triage and
access to neurosurgery and critical care showed
improved survival in patients with ICH admitted to
hospitals in Greater Manchester, UK [20]. Our
analyses of the second phase of INTEnsive blood
pressure Reduction in Acute Cerebral hemorrhage
Trial (INTERACT2) showed that the scoring of
abnormal baseline variables covering BP, glucose,
body temperature, and prior use of anticoagulants
independently predicted poor outcome in ICH [21].
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We therefore initiated the third INTEnsive care bundle
with blood pressure Reduction in Acute Cerebral
hemorrhage Trial (INTERACT3) with collaborators in 10
Asian, Latin American, and African countries (Appendix
1) to determine the effectiveness of a goal-directed care
bundle of active management involving early physiological
control (intensive BP lowering, glycemic control, and pyrexia treatment) and reversal of anticoagulation, compared
against usual standard of care. Using a pragmatic, one direction, stepped-wedge, cluster-randomized controlled trial
design, the aims are to provide evidence of the applicability
of a readily scalable, goal-directed protocol that could be
widely applied in clinical practice, while also providing information on the effectiveness of particular components
and across certain characteristics of patients. Herein, we report the final version of the trial protocol, compliant with
the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) reporting guideline (Appendix 2).

Objectives {7}
Hypothesis

A goal-directed care bundle of active management involving early physiological control (intensive BP lowering, glycemic control, and pyrexia treatment) and
reversal of anticoagulation improves functional outcome
after acute ICH.

Research questions

1. Does a goal-directed care bundle of active management involving early physiological control (intensive
BP lowering, glycemic control, and pyrexia treatment) and reversal of anticoagulation improve functional outcome after acute ICH compared to usual
standard of care (the null hypothesis is that there is
no difference in functional outcomes between treatment groups)?
2. Does a care bundle improve other clinical outcome
measures of death and dependency, separately on
death and physical function, health-related quality
of life (HRQoL), days of hospitalization, and living
circumstances, compared to usual care?
3. Does a care bundle reduce hematoma growth and
perihematomal edema?
4. Is there heterogeneity in the treatment effects
across particular patient characteristics?
5. Are there clinical benefits associated with the
separate components of the care bundle?
6. What factors support or impede the integration of a
care bundle protocol for ICH in hospital practice?
7. What are the costs of implementing the care
bundle?
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Trial design {8}
The INTERACT3 study is an international, multicenter,
prospective, stepped-wedge, cluster-randomized controlled, blinded outcome assessed (PROBE) trial, which
is being conducted through a network of investigators in
LMICs. After participating hospital sites commence in a
usual care “control” phase, they progressively transfer to
the intervention (care bundle) at pre-determined stages
through random allocation into 3 groups (Fig. 1). In
each phase, hospitals aim to reach an average target of
19 consecutive ICH patients who fulfill the eligibility criteria, but this number may vary from 1 to 50 patients according to service configuration and patient volumes.
However, each phase has a 3-month time limit, to ensure that the intervention period of the study is completed over 12 months. The study design is summarized
in Fig. 2.
Methods: participants, interventions, and
outcomes
Study setting {9}

The trial is being conducted in approximately 110
hospitals in 9 LMICs: Brazil, China, India, Mexico,
Nigeria, Pakistan, Peru, Sri Lanka, and Vietnam, and one
high-income country, Chile.
Eligibility criteria {10}
Hospital sites

Hospitals are eligible if they do not have any
organizational protocols for the management of ICH, or
if they use protocols different to those proposed in the
study and are comfortable about switching to the
proposed interventional bundle. All patients with acute

Fig. 1 Stepped-wedge design
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ICH who present to participating sites are included on a
register during the study period, with those fulfilling the
eligibility criteria included in the study. Brief details of
all patients with acute ICH who are screened but not
included, as well as those recruited, are recorded on the
screening/enrolment form. All eligible patients are
provided with an approved patient information sheet
(PIS) or patient responsible information sheet (PRIS)
and consent form (CF). A participant is anyone for
whom consent is obtained for permission to collect their
medical and personal information, and to be contacted
at 6 months for a follow-up assessment of their health
status.
Study patient characteristics

Patients are eligible to participate if they:
 Are an adult (aged ≥18 years)
 Have an acute stroke syndrome due to presumed

spontaneous ICH, defined as the sudden occurrence
of bleeding into the parenchyma of the brain that
may extend into the ventricles and, in rare cases,
into the subarachnoid space, confirmed by clinical
history and on CT brain imaging
 Present within 6 hours of the onset of symptoms
Patients with an ICH that is presumed secondary to a
medical treatment, for example antithrombotic or
anticoagulation therapy, are eligible, but those that
follow treatment with intravenous thrombolysis or
endovascular thrombectomy for acute ischemic stroke
are ineligible. If the precise timing of the first onset of
symptoms or signs of the qualifying event are unknown,
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Fig. 2 Study schema

then the time of onset is taken as the last time at which
the patient was known to be well.
Patients are excluded if they:
 Have definite evidence that the ICH is secondary to

a structural abnormality in the brain (e.g., an
arteriovenous malformation [AVM], intracranial
aneurysm, tumor, trauma, or previous cerebral
infarction)
 Have had recent thrombolysis/thrombectomy
 Have a high likelihood that the patient will not
adhere to the study treatment and/or follow-up
regimen
In each case, the decision about a patient’s eligibility is
based upon the attending clinician’s interpretation of
these eligibility criteria.

Consent process {26a}

Each participating site must obtain written approval(s)
from their hospital research ethics committee (EC) (e.g.,
institutional review board [IRB]), and any other relevant
regional or national body, before patient recruitment
commences (Appendix 3). A variable, mixed consent
process is used, according to local/national rules and
regulations:
 Cluster guardian consent or appropriate approval

(e.g., signed by the General Manager or Chief
Executive of the hospital, or Head of Neurology/
Neurosurgery/Stroke Department) for patients to
receive the randomized care bundle to be
implemented for patients acute ICH in the
Emergency Department, Stroke Unit, Intensive Care
Unit, or Neurology/Neurosurgery Wards

Song et al. Trials

(2021) 22:943

 Individual standard consent for the collection of

data through in-person assessment and data extraction from medical records during the hospital stay
and follow-up, and for release of personalized information for research purposes to allow centralized
follow-up at 6 months following admission
Additional consent provisions for collection and use of
participant data and biological specimens {26b}

The study consent process includes permission for
additional analysis of the collected data for systematic
reviews and individual patient data pooling projects. In a
subset of 1000 consecutive patients across sites, all brain
imaging over a 7–10-day period are collected and
uploaded in Digital Imaging and Communications in
Medicine (DICOM) format for analysis of the
characteristics of the ICH and underlying brain structure
at a core imaging laboratory at The George Institute for
Global Health (TGI), Sydney, Australia. No biological
specimens are collected.
Interventions
Explanation of the choice of comparators {6b}

The active comparator (intervention) is a goal-directed
care bundle that involves rapid correction (< 1 h) in
those participants who have abnormal physiological and
hematological variables during their in-hospital stay. The
intervention includes early intensive BP lowering, glucose control, treatment of pyrexia, and reversal of previous use of anticoagulants. Sites without a formal
institutional protocol on how to control BP, glucose,
fever, and previous anticoagulants usage in acute ICH
stage, or their protocol differentiated from the protocol
provided in this study were eligible. Each site will keep
their usual care or previous routine protocol before
transferring to intervention phase. The usual care phase
in place before switching to the intervention will act as
the control comparator. The intention of introducing
this intervention bundle is to enhance the implementation of guidelines or recommendations, narrow the gap
between evidence and practice in LMICs, and improve
outcome for patients with acute ICH. A one-direction
stepped-wedge cluster design was used to allow all hospitals to change to improved systems of care.
Intervention description {11a}

The care bundle involves one or more components
according to whether a participant has abnormal
physiological or hematological parameters, as outlined
below:
 Early intensive BP lowering, where the goal is to

achieve a target systolic BP level of < 140 mmHg
within 1 h of initiation, and to maintain this level for
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the next 7 days, or hospital discharge should this
occur earlier. Intravenous BP lowering is the
preferred treatment to commence as soon as
possible upon the patient’s admission. It is expected
that intravenous therapy will continue to be
required while any oral antihypertensive therapy is
initiated, in order to maintain smooth BP control. A
systolic BP of 130 mmHg is considered the lower
threshold in which the treatment is to cease. Each
site receives a standardized, stepped titratable,
intravenous BP lowering protocol, based on available
medications, that is established in advance.
 Intensive glucose control, where the goal is to achieve
a target blood glucose level of 6.1–7.8 mmol/L and
7.8–10.0 mmol/L for without and with diabetes
mellitus, respectively, and to maintain this level for
the next 7 days, or hospital discharge should this
occur earlier. In the intensive-treatment phase, a
continuous infusion of insulin (50 international units
[IU] in 50 mL of 0.9% sodium chloride for use in a
pump) is recommended to be started as soon as possible if the blood glucose level exceeds 7.8 mmol/L
and 10 mmol/L according to non-diabetes or diabetes, respectively. Adjustments of the insulin dose
are based on measurements of whole-blood glucose,
performed at 1- to 4-hourly intervals, with the aid of
a glucose analyzer. Patients can be fed continuously
with intravenous glucose at the time of admission,
but total parenteral, combined parenteral and enteral, or total enteral, feeding is instituted the following day according to a standardized schedule
whereby 20–30 non-protein kilocalories per kilogram of body weight per 24 h and a balanced composition (including 0.13 to 0.26 g of nitrogen per
kilogram per 24 h, and 20 to 40% of nonprotein calories in the form of lipids) is achieved as early as
possible.
 Treatment of pyrexia, where the goal is to achieve a
body temperature level < 37.5 °C within 1 h of
initiation and to maintain this level for the next 7
days, or hospital discharge should this occur earlier.
Measurement of temperature is according to local
practice. Patients allocated to the intensive group
are to receive measures of their body temperature
every 4 h over 72 h after admission. Patients with an
increase (≥37.5 °C) in body temperature are to
commence treatment as soon as possible, according
to a standardized anti-pyrexia treatment protocol,
based on available medications established in
advance.
 Reversal of anticoagulation, where the goal is to
achieve an international normalized ratio (INR) of <
1.5 within 1 h of treatment, and to maintain this
level for the next 7 days, or hospital discharge
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should this occur earlier. All patients with ICH are
to have a check of their blood INR immediately
upon presentation. Those with an elevated INR (>
1.5) who are allocated to the intensive group should
receive within 1 h of diagnosis: 5–10 mg of vitamin
K administered slowly intravenously; and according
to availability in the hospital, either intravenous
fresh frozen plasma (FFP) at 20 mL/kg, after blood
group typing or by using AB group plasma supplied
by local transfusion units; or 30 IU/kg of intravenous
four-factor prothrombin complex concentrate
(PCC). The speed of the infusion of FFP or PCC
should be as fast as the condition of the patient allows. Patients with an INR > 1.5 at 3 h after the start
of treatment are to receive PCC (if INR ≤2.0, 10 IU/
kg; if INR > 2.0, 30 IU/kg) as rescue treatment.
Criteria for discontinuing or modifying allocated
interventions {11b}

All hospitals are randomly assigned to the intervention and
encouraged to implement the intervention protocol as
completely as possible. However, they may modify sections
or skip them completely, according to clinical reasons.
Strategies to improve adherence to the intervention {11c}

The intervention protocol is given to investigators only
after completion of control phase. An online training is
organized for each site before starting the intervention.
Regular intervention quality reports are provided to each
site during intervention phase, and there is remote
communication and on-site monitoring to improve the
adherence to the intervention. Moreover, a process evaluation, designed to gain insights into the barriers and facilitators to change systems of care and implementation of
the protocol, is undertaken through formative stakeholder
engagement interviews during the course of the study.
Relevant concomitant care permitted or prohibited during
the trial {11d}

Medical or surgical treatments besides those required
within the care bundle are permitted during the study,
but they need to be recorded in the case report form
(CRF).
Provisions for post-trial care {30}

Not applicable. This study is evaluating a quality
improvement protocol for use of interventions that are
already available in routine practice which can
potentially be sustained beyond completion of the study.
Outcomes {12}

The primary outcome is functional recovery according
to the modified Rankin scale (mRS) measured at 6
months and analyzed as an ordinal outcome (shift across
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all scoring categories of physical function that range
from 0 to 5, and death as 6) [22].
Secondary outcomes include death or neurological
deterioration according to a change in scores on the
National Institute of Health stroke scale (NIHSS) [23] at
7 days, and poor outcome (defined by mRS scores 3–6),
separately on death and disability (mRS scores 3–5),
HRQoL using the EuroQoL Group 5-Dimension selfreport questionnaire (EQ-5D) [24], duration of hospital
stay, and residence, all measured at 6 months.
The safety outcomes of any all-cause and causespecific serious adverse events (SAEs) are recorded according to standard definitions for the duration of
follow-up.
Participant timeline {13}

The schedule of randomization for sites as well as
enrolment, treatment allocation, and assessments for
participants is outlined in the Table 1 and Fig. 2.
Sample size {14}

The study is designed with 90% power (α = 0.05) to
detect a 20% reduction in the odds (common odds ratio
of 0.80) of worse functional outcome using ordinal
logistic regression. Assuming a distribution of mRS in
the usual care control arm that is similar to that
observed in the standard BP control arm of the
INTERACT2 study [7] (i.e., 7.6%, 18.0%, 18.8%, 16.6%,
19.0%, 8.0%, and 12.0% for mRS scores of 0 to 6,
respectively), this corresponds to a 5.6% absolute
improvement in the proportion of patients experiencing
a poor outcome (mRS scores 3-6), that is from 55.6%
down to 50%. This also translates into a 10% relative risk
reduction (relative risk of 0.90). The combination of interventions as part of an intensive care bundle is assumed to provide a greater treatment effect than the use
of BP lowering alone (in INTERACT2, the treatment effect was 4% absolute).
The study plans to recruit 110 sites in a steppedwedge design consisting of 3 groups and 4 phases. Each
group would, therefore, include approximately 36 sites.
Assuming an intraclass correlation coefficient (ICC) of
0.044, which is similar to that of the INTERACT2 [7]
and Head Position in Acute Stroke Trial (HeadPoST)
[25] studies that included large numbers of hospitals in
China, each site would be required to recruit an average
of 18 patients per phase. Accounting for 5% of participants with a missing outcome, each site would need to
target an average of 19 patients per phase, thus leading
to a total sample size of 8360 patients (110 sites × 4
phases × 19 patients).
We recognize there will be variability in the number of
patients who will be recruited at each site, with very
large hospitals recruiting as many as 50 patients per
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Table 1 Assessment schedule
Evaluation

Screen/enrolment
log

Baseline

Day 1

72-h monitoring
chart

7 days or hospital separation
(discharge, transfer, or death)

6-month
follow-up

Forms

A

B

C

D/E

F

G

X

X

Screen

X

Eligibility

X

Consent/re-consent

X

Contact details

X

Vital signs

X

Physical parameters

X
X

GCS

X

NIHSS

X

Medical history

X

X

mRS

X

EQ-5D

X
X

Routine blood tests

X

Brain imaging

X

Standard stroke care

X

X
X

X
X

Final diagnosis

X

Medications in use

X

SAEs

X

X

X

X

X

X

EQ-5D EuroQoL Group 5-Dimension self-report questionnaire, GCS Glasgow Coma Scale, mRS modified Rankin scale, NIHSS National Institutes of Health stroke
scale, SAEs serious adverse events

phase while smaller hospitals may only recruit a few
patients per phase. If the sample size was inflated to
accommodate this issue as has been used in parallel
cluster trials [26] (e.g., using an inflation factor of
approximately 1.3), the sample size would need to reflect
25 patients per site per phase (i.e., 11,000 patients in
total). However, given that this adjustment would be a
very conservative scenario and that the effect of
variability in cluster sizes is expected to be mostly
mitigated by the randomization process, including
stratification by size [27], we have elected to maintain
the target average of 19 patients per site per phase for a
total sample size of 8360 patients. Assuming a worstcase scenario for the effect of cluster size variability on
power, this sample size would still provide at least 80%
power to determine the proposed treatment effect.

permuted blocks. Participating sites are stratified according to country and the estimated recruitment capacity
(ranging from 40, 80, 120, 160, and 200).

Recruitment {15}

Implementation {16c}

All eligible ICH patients who present to each
participating hospital from the start date are
prospectively and consecutively enrolled into the study.

In phase 1, all hospitals will be observed under usual
care “control” conditions according to usual
management of ICH patients. In phase 2, the first
cluster of hospitals (group 1) will start implementing the
intervention (care bundle), and then sequentially, groups
2 and 3 will start implementing the interventional
package in phases 3 and 4, respectively, so that by phase
4, all hospitals will be receiving the intervention, with
those in group 1 having the intervention for longest and

Assignment of intervention: allocation
Sequence generation {16a}

The unit of randomization is the hospital site, randomly
assigned by a statistician not otherwise involved in the
study using a pre-specified randomization schedule with

Concealment mechanism {16b}

A statistician not otherwise involved in the study will
randomly allocate hospitals into 3 groups, with each
group to assign the time of switching from usual care
(control) to care bundle (intervention) across hospital
sites. The randomization group will be notified to the
site within 2 weeks of the agreed date of commencing
the phase of study. All eligible ICH patients presenting
to participating hospitals from the start date will be
prospectively and consecutively enrolled, and when
assigned to the intervention phase will be managed with
the care bundle as usual clinical practice.
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those in group 3, the shortest. Once the site has
completed the necessary control usual care observational
period, they will receive training on the application of
the care bundle intervention during the study. The site
investigator will be informed to pause enrolment when
the patient number or study duration in control phase
has reached the pre-specified target, and then will be
instructed to transfer over to the intervention phase after
a recruitment interval of 7–10 days.
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number of the central office is provided on a small
card to patients and/or their relatives at the time of
discharge from hospital as a reminder to accept the
follow-up telephone call. Third, investigators collect a
range of contact information, including those of the
patient and of several relatives and/or friends. Finally,
the investigator will try to reassure patients and relatives of the telephone number to overcome any mistrust of unfamiliar telephone calls.

Assignment of interventions: blinding
Who will be blinded {17a}

Data management {19}

The treatment is open label to both investigators and
patients at sites. All other investigators, statisticians, and
endpoint assessors are blind to the treatment allocation,
who are trained to collect outcome measures by
telephone at 6 months.

Hospital sites receive paper versions of the CRFs and
a procedure manual to serve as a reference guide in
using the database; each data element is defined to
ensure investigators are accurate and consistent in
data entry. All data entry is completed using a
password-protected Internet-based data management
system which allows individual log-in; all investigators and coordinating/monitoring research staff are
required to ensure security, privacy and confidentiality. Only research staff listed on site delegation logs
are given access to the data management system,
which allows real time data entry and the generation
of queries for values entered outside of valid ranges,
and for consistency checking. All computerized forms
are electronically signed (by use of the unique password) by authorized study staff; all changes made following the initial entry have an electronic dated
audit trail.

Procedures for unblinding if needed {17b}

Not applicable. This study is an unblinded, hospital-level
intervention.

Data collection and management
Plans for assessment and collection of outcomes {18a}

Hospitals are required to collect data on participating
patients at admission (baseline), 72 h monitoring chart,
separation (day 1; day 7 or at discharge if earlier,
transfer from the hospital or death), and all SAEs
including death until the 6 months of follow-up. The 6month assessments will be conducted by an appropriately trained independent outcome assessor, using an
assigned telephone script and kept blind to the treatment allocation. The assessor will be managed by the regional office in each country.
Table 1 illustrates the schedule and nature of the data
collection required during the study period.
Plans to promote participant retention and complete
follow-up {18b}

The centralized follow-up assessment is anticipated to
be more challenging than in conventional individualpatient clinical trials because the study uses broad inclusion criteria and the consecutive recruitment of
patients; there is a high “floating” population in
LMICs where people often change their mobile telephone numbers; and there is a relatively long interval
between the time of discharge from hospital and
follow-up (6 months). Several strategies are used to
ensure that the rate of lost-to-follow-up is kept low.
First, investigators emphasize to participating patients
(and their responsible person[s]) during the consent
process that they are to receive a telephone call from
a person in a centralized office to check on their
health status at 6 months. Second, the telephone

Confidentiality {27}

Every precaution is taken to respect the privacy of
participants in the conduct of the study. Only deidentified data will be used for statistical analysis and the
publication of results to maintain confidentiality. However, as a part of the centralized follow-up service, the
International Coordinating Center (ICC) at TGI and Regional Coordinating Centers (RCCs) will use contact
sources recorded by the hospital sites. Only name, telephone numbers, next of kin, and primary medical practitioner contact details (if applicable) are sent to the
follow-up center for the follow-up assessments. The information is encrypted and password-protected using an
MS Excel lock form before being sent by email in
batches. This information is included in the PIS and
PRIS. In the course of monitoring for data quality and
adherence to the study protocol, research staff will refer
to source documents (medical records) at participating
hospitals. This information is also included in the PIS
and PRIS. All individual and site information will be deidentified in reports and results to further protect the
confidentiality of participants.
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Plans for collection, laboratory evaluation, and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}

Not applicable. Biological specimens are not collected as
part of this study.

Statistics methods
Statistical methods for primary and secondary outcomes
{20a}

All analyses will be undertaken at the patient level on an
intention-to-treat (ITT) basis at each site using generalized estimating equations (GEE) or random-effects regression to account for clustering. The primary outcome
of a shift (improvement) in scores on the mRS at 6
months will be analyzed by means of an ordinal logistic
regression, with mRS as a dependent variable with 7
levels (0 [no residual symptom] to 6 [death]). The model
will include the trial phase (1 to 4), the randomized arm
(control or intervention) corresponding to each phase,
and the size of the site (as used in the stratification). The
secondary outcome of neurological change at 7 days will
be analyzed with the same method [28]. Binary and continuous secondary outcomes will be analyzed using a
similar approach but using logistic and linear regression,
respectively.
All analyses will be adjusted for clustering within
center, hospital size (stratification variable), and for trial
phase. In addition, sensitivity analyses will be conducted
after considering potential prognostic variables as well as
the effect of time to adjust for potential background
secular trends, including the potential impact of the
COVID-19 pandemic.
No adjustment for multiplicity is planned as there are
only a small number of pre-specified efficacy outcomes
being investigated. A detailed statistical analysis plan will
be finalized before unblinding and database locked and
posted on a pre-print server.
Interim analyses {21b}

Two “formal interim analysis” meetings will be held by
Data and Safety Monitoring Board (DSMB) by
teleconference (or face-to-face, if possible) to review data
relating to treatment efficacy, patient safety, and quality
of trial conduct.
A recommendation to discontinue INTERACT3
prematurely will be based upon there being clear
evidence that the treatment provides protection or
causes harm for an important clinical outcome.
The DSMB will work on the principle that a difference
of at least 3 standard errors in an interim analysis of a
major outcome event (e.g., death from all causes or
independent survival at 6 months) between patients
allocated to the intensive or the control group, to justify
halting, or modifying the study, before the planned
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completion of recruitment. Given the minimal impact of
this approach on the type-I error rate, no adjustment is
made to the final significance level [29].
Methods for additional analyses {20b}
Substudy—effects of treatment of hematoma growth in ICH

The effects of treatment on hematoma expansion and
other indices including perihematomal edema will be
evaluated in a subsample of 1000 patients (the earliest 7
recruitments in each of the control and intensive groups,
respectively, for each site). Apart from the baseline CT
scan, repeat CT scans (24 ± 3 h and 7 days) are required.
CT imaging will be conducted according to standardized
techniques and uploaded to purpose-built server, either
directly from the hospital site (if they have suitable
broadband internet) or via the RCC office. The LCC will
keep a hard copy in an uncompressed DICOM format
onto a CD-ROM for monitor site verification. The imaging data will be analyzed centrally by experts who will
be kept blind to the treatment allocation. The primary
efficacy measure is proportional absolute and relative
changes (“growth”) in hematoma and perihematomal
volumes according to standard measures at 24 h. Background measures of cerebral small vessel disease and
“brain frailty” will also be recorded. Clinical outcomes
are assessed over 6 months.
Process evaluation

In order to explore how the care bundle, a complex
intervention, is implemented, as well as to understand
clinicians’ perspectives, a prospective process evaluation
will be conducted alongside the roll-out of the trial.
Intervention fidelity, reach, dose, adoption, feasibility,
and appropriateness of the goal-directed care bundle will
be evaluated within the trial. Contextual conditions
(current policies, settings resources, etc.) that may have
impacted on the quality of the implementation are being
assessed.
A mixed methods analytical approach is being used to
address the objectives of process evaluation, with
questions and indicators informed by the process
evaluation framework of the Medical Research Council
(MRC) [30]. The normalization process theory (NPT),
which has been used for assessing how guidelines are
embedded into routine practice, will serve as a
conceptual framework to explore systematically how
overall and for each of the interventions were adopted
into patient care [31]. To assess the implementation and
mechanism of impact of the interventions, semistructured interviews and non-participants observations
will be conducted among the primary implementers (physicians and nurses) using structured interview guides and
observation templates. Focus group discussions will be
conducted with project operation staff and site principal
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investigators to explore facilitators and barriers to the care
bundle delivery by different stakeholders. Observational
records, including hospital organization questionnaires,
routine monitoring data, field notes, and CRFs, will also
be used to triangulate qualitative findings to assess implementation quality, acceptability of the care bundle, and
contextual factors, which may have impacted on outcomes. Sites involved in the process evaluations will be determined by purposive sampling in accordance with the
pre-specified criteria to achieve representativeness. Results
of the process evaluation will be used to monitor and
document project implementation, as well as identify barriers, which the coordinating team uses to address in a
timely fashion, such as increasing the confidence of clinicians in managing the intervention by providing them
with additional training.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}

All analyses including the primary analysis, will be conducted
on the ITT population and using all available data. If more
than 5% of patients have a missing primary outcome, we will
use multiple imputations for sensitivity analysis.
Plans to give access to the full protocol, participant-level
data, and statistical code {31c}

The data collected is owned by the TSC. Datasets
generated and/or analyzed will be available to all study
investigators, and to investigators at other institutions
around the world, according to a data sharing agreement.
Data sharing will be available from 12 months after
publication of the main results. Investigators are to make
a formal request for data sharing through the Global
Research Committee (GRC) of TGI, and according to a
data sharing policy (https://georgeinstitute.sharepoint.
com/TGIPolicy/Data%20Sharing%20Policy.pdf).
Access
will be controlled by the Principal Investigators (PIs) with
the approval of the TSC.

Oversight and monitoring
Composition of the coordinating center and TSC {5d}
TSC

The TSC (independent Chair) will comprise
independent members, the principal investigators,
national leaders, expert academic researchers, patient
representatives, and an observer from Medical Research
Council (MRC) and will be governed by a Charter
(Appendix 4). The TSC is responsible for overseeing the
execution of the study design, protocol, data collection,
and analysis plans, as well as publications.
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study, data and project management, committee coordination, assistance with ethics committee and regulatory applications, protocol and procedures for training of participating
sites, overseeing of initiation visits and activation of participating centers, monitoring of data quality and adherence to
protocol, applicable guidelines and regulations, preparation
of study data for analysis, and publication.
Composition of the data monitoring committee, its role,
and reporting structure {21a}
DSMB

The DSMB is independent of the sponsor and
responsible for reviewing the safety, ethics, and
outcomes of the study. The DSMB is governed by a
Charter outlining responsibilities, procedures, and
confidentiality, and reviews the accumulating unblinded
data at regular intervals (Appendix 5).
SAE reporting and harms {22}

An SAE is defined according to standard convention as
any untoward medical occurrence that results in any of
the following: (i) results in death; (ii) is life threatening
in the opinion of the Investigator (at the time of the
event); (iii) requires admission to hospital or
prolongation of an existing hospital stay; (iv) results in
persistent or significant disability or incapacity; (v)
results in congenital anomaly or birth defect; or (vi) is
an important medical event in the opinion of the
Investigator that is not immediately life-threatening and
does not result in death or hospitalization but which
may jeopardize the patient or may require intervention
to prevent one of the other listed outcomes.
An SAE form is provided for recording details that
includes the event diagnosis, classification of the event
using standard definitions, the Investigator’s opinion on the
causal relationship to the care bundle, and the timing of the
event. The Investigator will be responsible for ensuring that
details of investigations and outcomes of an SAE are
finalized. The SAE should be documented in the medical
records or patient file, and signed and dated by the
investigator, for audit and monitoring. All SAEs are
reviewed by a medical monitor assigned to the trial. Safety
outcomes are reported to the presiding Ethics Committees
in line with their requirements every 6 months, as well as
for review by the DMSB at each meeting.
Frequency and plans for auditing trial conduct {23}

There are no plans for auditing trial conduct.

CCC

Plans for communicating important protocol
amendments to relevant parties (e.g., trial participants,
ethics committees) {25}

The CCC is based at TGI China, supported by project staff,
and is responsible for the day-to-day management of the

All protocol amendments are approved by the TSC and
communicated to co-investigators, commercial partners,
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and national leaders, who are responsible for study conduct in their country. The amended protocol can be implemented only after review and approval by ethics
committees.
Dissemination plans {31a}

In addition to relevant reports developed in formats
suitable for various stakeholders, the findings will be
published in high impact journals, presented at national
and international conferences on stroke, cardiovascular
disease, and hypertension. A series of seminars will be
held at the end of the study, across China and in other
participating LMICs, targeting academics, researchers,
clinicians, and local health officers. Discussion and
debate will assist in integrating the results, whatever the
findings, into clinical practice and to influence the
decisions of guideline and policy makers. Patient
representatives are invited to attend TSC meetings and
are asked to review study materials to ensure that the
findings are able to be disseminated in an
understandable manner to a broader audience.

Discussion
INTERACT3 was initiated as a vanguard “start-up”
phase in China in December 2017 and subsequently
expanded to other countries following receipt of MRC
grant funding in late 2019 that provides the necessary
resources to achieve the required sample size and
strengthen the generalizability and impact of the results.
However, conduct of the study has been adversely
impacted by COVID-19 since January 2020. This led to
a decline in the recruitment of patients in China and
postponement of site activation elsewhere. Although the
pandemic was well controlled in China during 2020,
most of the other participating countries have had ongoing restrictions imposed by COVID-19; even so, they
are on schedule for activation and roll-out in early 2021.
There have been challenges to implementing the
intensive care bundle and data collection, as some
investigators in LMICs have limited research experience,
lack familiarity with Good Clinical Practice
requirements, and have busy workloads. Quality control
performance metrics covering the intervention variables
at study and site levels are reported to sites on a
monthly basis. Efforts to address issues identified
through monitoring and the process evaluation have
been undertaken in training sessions at investigator
meetings and teleconferences, and with individual site
investigators. The learnings gained in China are used to
inform quality control systems introduced in the other
countries.
INTERACT3 is the largest clinical trial in ICH that
can address ongoing uncertainties over the effectiveness
of early intensive BP lowering as well as the utility of
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managing other abnormal physiological variables, rapid
correction of anticoagulation, and more broadly of an
active management protocol in this serious condition.
The pragmatic cluster clinical trial design of
INTERACT3 allows the recruitment of a broad range of
patients, many of whom have large hematomas or
require early surgical intervention that were purposely
excluded from previous clinical trials of early BP
lowering. The results of this study will inform the
effectiveness of a widely applicable goal-directed care
bundle in acute ICH.

Trial status
The study has been approved by relevant ethics
committees and regulatory bodies at country level and
local sites in China, Chile, Peru, Pakistan, Brazil, Mexico,
Vietnam, Sri Lanka, India, and Nigeria. According to
funding request from MRC, an additional approval had
been obtained from Research Ethics Committee (REC)
of the University of Leicester, UK.
Patient enrolment commenced in December 2017 and
is planned to end on 30 March 2022. As of 31
December 2020, 5917 participants have been enrolled at
93 sites from China, Chile, Peru, Brazil, and Pakistan.
The current protocol is version 3.0, and all protocol
updates have been approved by TSC and Ethics
Committees and communicated with investigators and
DSMB members.
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